Selank is a synthetic heptapeptide analogue of endogenous immunomodulator tuftsin stabilized with a C-terminal Pro-Gly-Pro tripeptide, studied for GABA-A modulation, enkephalin preservation, and hippocampal BDNF expression.
Scientific Profile & Research Key Points: Selank
Selank is a synthetic heptapeptide analogue of endogenous immunomodulator tuftsin stabilized with a C-terminal Pro-Gly-Pro tripeptide, studied for GABA-A modulation, enkephalin preservation, and hippocampal BDNF expression.
Active Batch Release Specifications (Lot SL-2026-153)
Analytical release verification for current Selank (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-153 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water or sterile saline (>10 mg/mL)
Temperature & Stability
Store lyophilized at -20°C; refrigerate solution at 2°C–8°C for up to 28 days.
Selank — Technical Questions & Answers
What is the molar concentration when reconstituting Selank (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of Selank (MW 751.87 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 3.33 mM (3,325 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does Selank's counterion stoichiometry affect assay mass calculations?
Selank (CAS 129954-34-3, formula C33H57N11O9) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify Selank Lot SL-2026-153 and what pathway does it target?
Lot SL-2026-153 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 751.87 g/mol. In preclinical literature, Selank targets GABA-A allosteric modulation, enkephalinase inhibition & IL-6/BDNF gene expression (Volkova A. et al., Front Pharmacol (2016) — Selank modulation of GABAergic neurotransmission gene expression (PMID: 26924985)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
Selank vs Semax: Comparative Heptapeptide Chemistry, BDNF Upregulation, and GABAergic Modulation
A structural and pharmacological comparison of Russian-developed regulatory heptapeptides: Semax (ACTH 4-10 analogue) vs Selank (Tuftsin analogue). Molecular pathways and stability.
How to Read a Peptide Certificate of Analysis (COA): Step-by-Step Breakdown
A practical guide for researchers. How to analyze HPLC chromatograms, verify retention time, interpret mass spec m/z peaks, evaluate counterion salt ratios, and spot fraudulent documents.
How to Reconstitute Research Peptides: Complete Laboratory Protocol and Best Practices
Standard Operating Procedure (SOP) for peptide reconstitution. Diluent selection (BAC water vs acetic acid), meniscus calculations, avoiding foaming, and cold storage parameters.